

PRODUCT DATASHEET

Ready-to-Assay™ APJ Apelin Receptor Frozen Cells

CATALOG NUMBER: HTS068RTA

CONTENTS: Pack contains 2 vials of mycoplasma-free cells, 1 ml per vial. Fifty (50) mL of Media Component.

STORAGE: Vials are to be stored in liquid N₂. Media Component at 4°C (-20°C for prolonged storage).

BACKGROUND

Ready-to-Assay GPCR frozen cells are designed for simple, rapid calcium assays with no requirement for intensive cell culturing. Eurofins Discovery Services has optimized the freezing conditions to provide cells with high viability and functionality post-thaw. The user simply thaws the cells and resuspends them in media, dispenses cell suspension into assay plates and, following over night recovery, assays for calcium response.

Apelin peptides have been discovered to be a family of peptides of different sizes that is derived from the N-terminus of a 77 amino acid precursor peptide (preproapelin) (Hosoya et al., 2000). Apelin receptor (APJ) is a G protein-coupled receptor that is activated by several apelin fragments, which results in inhibition of cAMP production (Habata et al., 1999). APJ and apelin peptides have been found to be involved in the regulation of cardiovascular function (Katugampola et al., 2001) and fluid homeostasis (Reaux et al., 2001). Broad roles of apelin system has been established in lowering blood pressure, as a potent cardiac inotrope, in modulating pituitary hormone release and food and water intake, in stress activation, and as a novel adipokine that is excreted from fat cells and regulates insulin (Lee et al., 2006). Cloned human APJ-expressing cell line is made in the Chem-5 host, which supports high levels of recombinant APJ expression on the cell surface and contains optimized levels of a recombinant promiscuous G protein to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for agonists, antagonists and modulators at APJ

USE RESTRICTIONS

Please see User Agreement (Label License) for further details. One such restriction is that the contents of the supplied vial(s) are limited to a single use and shall not be propagated and/or re-frozen by licensee.

WARNINGS

For Research Use Only; Not for Use in Diagnostic Procedures Not for Animal or Human Consumption

GMO

This product contains genetically modified organisms.

Este producto contiene organismos genéticamente modificados.

Questo prodotto contiene degli organismi geneticamente modificati.

Dieses Produkt enthält genetisch modifizierte Organismen.

Ce produit contient organismes génétiquement des modifiés.

Dit product bevat genetisch gewijzigde organismen.

Tämä tuote sisältää geneettisesti muutettuja organismeja.

Denna produkt innehåller genetiskt ändrade organismer.

APPLICATIONS

Calcium Flux Assays

APPLICATION DATA




Figure 1. Representative data for activation of APJ receptor. Calcium flux in APJ–expressing Chem-5 cell line induced by Apelin-13 APJ–expressing Chem-5 cells were loaded with a calcium dye, and calcium flux in response to the indicated ligand(s), 4-fold serial dilution with each concentration performed in duplicate, was determined on a Molecular Devices FLIPRTETRA plus ICCD. Maximal fluorescence signal obtained in this experiment was 22,000 RLU (Relative Light Units).

Table 1. EC₅₀ values of APJ -expressing Chem-5 cells with values described in the literature.

LIGAND	ASSAY	POTENCY (nM)	REFERENCE
Apelin-13	Calcium Flux	2.5	Eurofins Internal Data
Apelin-13	Calcium Flux	22.4	Medhurst et al., 2003

ASSAY SETUP

- 1. Immediately upon receipt, thaw cells or place cells in liquid nitrogen.
- Thaw cells rapidly by removing from liquid nitrogen and immediately immersing in a 37°C water bath. Immediate after ice has thawed, sterilize the exterior of the vial with 70% ethanol.
- 3. Add 1mL of pre-warmed Media Component to each vial of cells. Place contents from two vials into a 15 mL coni tube and bring the volume to 10 mL of Media Component.
- 4. Centrifuge the cell suspension at 190 x g for four minutes
- 5. Remove supernatant and add 10.5 mL of pre-warmed Media Component to resuspend the cell pellet.
- Seed cell suspension into appropriate assay microplate (100 μL/well for 96-well plate, 25 μL/well for 384-well plate)
- 7. When seeding is complete, place the assay plate at room temperature for 30 minutes.
- 8. Move assay plate to a humidified 37°C 5% CO2 incubator for 24 hours.
- After 24 hour incubation, remove assay plate from the incubator and wash sufficiently with Hank's Balanced Salt Solution (HBSS) supplemented with 20mM HEPES, 2.5mM Probenecid at pH 7.4 to remove all trace of Media Component.
- 10. Prepare Fluo-8, AM (AAT Bioquest: 21080) Ca2+ dye by dissolving 1mg of Fluo-8 NW in 200 μL of DMSO. Onc



Discovery Services

dissolved place 10 μ L of Fluo-8 NW Ca²⁺ dye solution into 10 mL of HBSS 20mM HEPES, 2.5mM Probenecid p buffer and apply to assay microplate (Ca²⁺ dye at 10 μ L /10 mL is sufficient for loading one (1) microplate).

- 11. Set-up FLIPR to dispense 3x ligand to appropriate wells in the assay plate. Set excitation wavelength at 470-49 (FLIPR^{TETRA}) or 485 nm (FLIPR1, FLIPR2, FLIPR3) and emission wavelength at 515-565 nm (FLIPR^{TETRA}) or emission filter for Ca²⁺ dyes (FLIPR1, FLIPR2, FLIPR3). Set pipet tip height to 5 μL below liquid level and disperate to 75 μL/sec (96-well format) or 50 μL/sec (384-well format). Set up plate layout and tip layout for each individual experiment. Set time course for 180 seconds, with ligand addition at 10 seconds.
- 12. Ligands are prepared in non-binding surface Corning plates (Corning 3605 96-well or Corning 3574 384-we
- 13. After the run is complete, negative control correction is applied and data analyzed utilizing the maximum statisti

ASSAY MATERIALS

Description	Supplier and Product Number
HBSS	Hyclone: SH3026802
HEPES 1M Stock	EMD Millipore.: TMS-003-C
Probenicid	Sigma: P8761
Quest Fluo-8 ^{1M} , AM	AAT Bioquest: 21080
U-50488 ligand	Sigma: D8040
Non-binding white plates (for ligand prep)	Corning: 3605(96-well)/3574(384-well)
Black (clear bottom) tissue-culture treated plates	Corning: 3904(96-well)/3712(384-well)

FLIPR SETTINGS

Settings for FLIPR TETRA® with ICCD camera option

Option	Setting
Read Mode	Fluorescence
Ex/Em	Ex470_495 / Em515_575
Camera Gain	2000
Gate Open	6 %
Exposure Time	0.53
Read Interval	1s
Dispense Volume	50 μl (25 μl for 384-well)
Dispense Height	25 µl (50 µl for 384-well)
Dispense Speed	75 μl L/sec (50 μl for 384-well)
Expel Volume	0 μΙ
Analysis	Subtract Bias Sample 1

HOST CELL

Chem-5, an adherent rat hematopoietic cell line expressing endogenous $G \cdot 15$ protein as well as an exogenous proprietary promiscuous $G \alpha$ protein.

EXONGENOUS GENE EXPRESSION

APJ cDNA (Accession Number: U03642; see CODING SEQUENCE below) expressed from a proprietary expressed from a proprietary pHS plasmid.



Discovery Services

CODING SEQUENCE

1 - ATG GAG GAA GGT GGT GAT TTT GAC AAC TAC TAT GGG GCA GAC AAC CAG TCT GAG TGT GAG - 60 G D F D N Y 61 - TAC ACA GAC TGG AAA TCC TCG GGG GCC CTC ATC CCT GCC ATC TAC ATG TTG GTC TTC CTC - 120 G A $121 \ - \ \mathsf{CTG} \ \mathsf{GGC} \ \mathsf{ACC} \ \mathsf{ACG} \ \mathsf{GGA} \ \mathsf{AAC} \ \mathsf{GGT} \ \mathsf{CTG} \ \mathsf{GTG} \ \mathsf{CTC} \ \mathsf{TGG} \ \mathsf{ACC} \ \mathsf{GTG} \ \mathsf{TTT} \ \mathsf{CGG} \ \mathsf{AGC} \ \mathsf{AGC} \ \mathsf{CGG} \ \mathsf{GAG} \ \mathsf{AAG} \ - \ \mathsf{180} \ \mathsf{41} \ - \ \mathsf{L} \ \mathsf{G} \ \mathsf{T} \ \mathsf{T} \ \mathsf{G} \ \mathsf{G} \ \mathsf{AG} \ \mathsf{CGG} \ \mathsf{GAG} \ \mathsf{AAG} \ - \ \mathsf{180} \ \mathsf{G} \ \mathsf{G$ 181 - AGG CGC TCA GCT GAT ATC TTC ATT GCT AGC CTG GCG GTG GCT GAC CTG ACC TTC GTG GTG - 240 61-R R S A D I F I A S L A V A D L T F V 241 - ACG CTG CCC CTG TGG GCT ACC TAC ACG TAC CGG GAC TAT GAC TGG CCC TTT GGG ACC TTC - 300 361 - ACC GGC CTC AGC TTC GAC CGC TAC CTG GCC ATC GTG AGG CCA GTG GCC AAT GCT CGG CTG - 420 V R P $421 - \text{AGG CTG CGG GTC AGC GGG GCC GTG GCC ACG GCA GTT CTT TGG GTG CTG GCC GCC CTC CTG} \\ - 480 \\ 141 - R & L & R & V & S & G & A & V & A & T & A & V & L & W & V & L & A & A & L & L & -160 \\ \end{array}$ $481 - GCC \ ATG \ CCT \ GTC \ ATG \ GTG \ TTA \ CGC \ ACC \ GGG \ GAC \ TTG \ GAG \ AAC \ ACC \ AAG \ GTG \ CAG - 540 \\ 161 - A M P V M V L R T T G D L E N T T K V Q - 180 \\$ $541 - \mathtt{TGC} \ \mathtt{TAC} \ \mathtt{ATG} \ \mathtt{GAC} \ \mathtt{TAC} \ \mathtt{TCC} \ \mathtt{ATG} \ \mathtt{GTG} \ \mathtt{GCC} \ \mathtt{ACT} \ \mathtt{GTG} \ \mathtt{GAC} \ \mathtt{TCA} \ \mathtt{GTG} \ \mathtt{GT$ 661 - TAC TTC TTC ATC GCC CAA ACC ATC GCT GGC CAC TTC CGC AAG GAA CGC ATC GAG GGC CTG - 720 $721 - \texttt{CGG} \ \texttt{AAG} \ \texttt{CGG} \ \texttt{CGG} \ \texttt{CGG} \ \texttt{CTG} \ \texttt{CTC} \ \texttt{AGC} \ \texttt{ATC} \ \texttt{ATC} \ \texttt{GTG} \ \texttt{GTG} \ \texttt{CTG} \ \texttt{GTG} \ \texttt{GTG} \ \texttt{ACC} \ \texttt{TTT} \ \texttt{GCC} \ \texttt{CTG} \ \texttt{TGC} \ - \ 780 \ \texttt{241} - \texttt{R} \ \texttt{K} \ \texttt{R} \ \texttt{R} \ \texttt{L} \ \texttt{L} \ \texttt{S} \ \texttt{I} \ \texttt{I} \ \texttt{V} \ \texttt{V} \ \texttt{L} \ \texttt{V} \ \texttt{V} \ \texttt{V} \ \texttt{T} \ \texttt{F} \ \texttt{A} \ \texttt{L} \ \texttt{C} \ - \ 260 \ \texttt{CTG} \ \texttt{CTG}$ 781 - TGG ATG CCC TAC CAC CTG GTG AAG ACG CTG TAC ATG CTG GGC AGC CTG CAC TGG CCC - 840 841 - TGT GAC TTT GAC CTC TTC CTC ATG AAC ATC TTC CCC TAC TGC ACC TGC ATC AGC TAC GTC - 900 901 - AAC AGC TGC CTC AAC CCC TTC CTC TAT GCC TTT TTC GAC CCC CGC TTC CGC CAG GCC TGC - 960 961 - ACC TCC ATG CTC TGC TGT GGC CAG AGC AGG TGC GCA GGC ACC TCC CAC AGC AGC AGC AGG ~ 1020 M L C C G Q S R A G 1081 - GGT GGA GAA CAG ATG CAC GAG AAA TCC ATC CCC TAC AGC CAG GAG ACC CTT GTG GTT GAC - 1140 361 - G G E O M H E K S I P Y S Q E T L V V D - 380 E Q M H E K S I P 1141 - TGA

RELATED PRODUCTS

PRODUCT NUMBER DESCRIPTION

HTSCHEM-1RTA Ready-to-Assay™ Chem-1 host frozen cells (control cells)

HTS068M ChemiScreen™ APJ Apelin receptor membrane prep

* Note: Chem-5 cells are derived from Chem-1 cells

REFERENCES

1. Habata Y et al. (1999) Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim. Biophys. Acta 1452: 25-35.



- 2. Hosoya M et al. (2000) Molecular and functional characteristics of APJ: Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275: 21061–21067.
- Katugampola SD et al. (2001) [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br. J. Pharmacol. 132: 1255-1260.
- 4. Lee DK et al. (2006) Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol. Sci. 27: 190-194.
- 5. Medhurst AD et al. (2003) Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J. Neurochem. 84: 1162-1172.
- Reaux A et al. (2001) Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neurochem. 77: 1085-1096.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTICPROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

User Agreement (Label License)

In addition to the General Terms and Conditions section, thee specific terms also apply for Ready-to-Assay™ APJ Apelin Receptor Frozen Cells, Product No. HTS068RTA

BY USING THE THIS PRODUCT LICENSED TO YOU ("LICENSEE") HEREUNDER, YOU ARE HEREBY REPRESENTING THAT YOU HAVE THE RIGHT AND AUTHORITY TO LEGALLY BIND YOURSELF OR YOUR COMPANY, AS APPLICABLE, AND ARE CONSENTING TO BE LEGALLY BOUND BY ALL OF THE TERMS OF THIS USER AGREEMENT ("AGREEMENT"). IF YOU DO NOT AGREE TO ALL THESE TERMS, DO NOT USE THE PRODUCT, AND IMMEDIATELY RETURN SUCH PRODUCTS TO THE APPLICABLE SELLER FOR A REFUND. This is a legal agreement between Licensee and Eurofins Pharma Bioanalytics Services US Inc. governing use of the Ready-to-Assay Cells products and/or any accompanying operating/use protocols (the "Product(s)") provided to Licensee.

LICENSEE shall obtain no ownership interest in the Product or use/culture protocols accompanying the Product other than through the perpetual limited license granted herein. If the Product is licensed through an authorized Eurofins Pharma Bioanalytics Services US Inc. distributor, Licensee shall be obligated to disclose its identity to Eurofins Pharma Bioanalytics Services US Inc. to insure compliance with this User Agreement.

Limited License and Restrictions. Pursuant to the terms and conditions of this Agreement, Eurofins Pharma Bioanalytics Services US Inc. conveys to Licensee the non-exclusive and non-transferable right to use the Licensed Product only for Research Purposes conducted by Licensee (whether Licensee is an academic user or a for-profit entity). "Research Purposes" means any biological research and development application or use, including without limitation, developing, demonstrating or validating biological assays, life sciences and/or pharmaceutical research. "Research Purposes" excludes applications outside biology (including but not limited to consumer electronics or materials sciences), and specifically excludes the following applications of whatever kind or nature: Clinical Diagnostics (any use of a product or service for clinical diagnosis where data from an individual's sample is given to such individual or used for the purpose of diagnosis or treatment of a medical condition in such individual, where that result may be used in the treatment of such individual), therapeutics, clinical imaging, environmental testing and cosmetics. Contents of the supplied vial(s) are limited to a single use and shall not be propagated and/or re-frozen by licensee. Licensee cannot sell or otherwise transfer (a) this Product or (b) materials made using this Product to a third party. Licensee may transfer information or materials made through use of this Product to a scientific collaborator, provided that such transfer is not for the commercial purposes, and that such collaborator agrees in writing: (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for Research Purposes and not for commercial purposes. Commercial purposes means any activity by a user of the Product for consideration that may include, but is not limited to: (1) operating a service business that uses the



Discovery Services

Products to develop information or data which is resold for research and development applications; (2) use of the Product in manufacturing; (3) use of the Product for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the Product, whether or not such Product is resold for use in research. Licensee expressly represents and warrants to Eurofins Pharma Bioanalytics Services US Inc. that Licensee will properly test and use any Product purchased from Eurofins Pharma Bioanalytics Services US Inc. or its affiliated companies in accordance with the practices of a reasonable person who is an expert in the field and in strict compliance with all applicable laws and regulations, now and hereinafter enacted. Licensee agrees to comply with instructions, if any, furnished by Eurofins Pharma Bioanalytics Services US Inc. relating to the use of the Product and to not misuse the Product in any manner. Licensee shall not reverse engineer, disassemble or modify the Product or create any derivative works of the written materials accompanying the Product, including but not limited to any material data sheets or similar materials with respect to the Products' specifications. Licensee acknowledges that Eurofins Pharma Bioanalytics Services US Inc. or its affiliated companies retains ownership of all patents, copyrights, trademarks, trade secrets and other proprietary rights relating to or residing in the Product or any portion thereof.

Term and Termination. This Agreement commences upon Licensee's use of the Products, and shall remain in effect in perpetuity unless terminated sooner as set forth hereunder. Eurofins Pharma Bioanalytics Services US Inc. may terminate this Agreement immediately if Licensee breaches any provision herein. Upon any such termination, all rights granted to Licensee hereunder will immediately terminate, and Licensee shall immediately cease using the Product and, at Eurofins Pharma Bioanalytics Services US Inc.'s option, return or destroy all Products (certifying such destruction to Eurofins Pharma Bioanalytics Services US Inc. in writing).

Assignment. Licensee shall not sublicense, assign (by operation of law of otherwise) or otherwise transfer this Agreement or any of the rights or licenses granted under this Agreement without the prior written consent of Eurofins Pharma Bioanalytics Services US Inc.. Any attempted assignment, sublicense or transfer by Licensee without such consent shall be null and void.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services